Semaglutide vs Tirzepatide: A Research Comparison

Semaglutide and tirzepatide are two of the most widely studied incretin-mimetic peptides, but they are structurally and pharmacologically distinct. Semaglutide is a 31-amino-acid GLP-1 analog (~4,114 Da) that activates only the GLP-1 receptor. Tirzepatide is a 39-amino-acid peptide (~4,814 Da) engineered from the GIP backbone that activates both the GIP and GLP-1 receptors, with imbalanced potency in favour of GIP-R. Both are FDA-approved medicines and are also sold, separately, as For Research Use Only research peptides — the research vial is not the approved drug.

Updated August 30, 2026 · Peptide Research Guides · ~10 min read

What Is Semaglutide?

Semaglutide is a synthetic 31-residue peptide analog of human glucagon-like peptide-1 (GLP-1), corresponding to positions 7–37 of the native hormone with three engineered modifications: alanine-8 substituted with α-aminoisobutyric acid (Aib) to resist DPP-4 cleavage, lysine-34 substituted with arginine, and lysine-26 acylated with a C18 fatty diacid via a γ-Glu/2xOEG spacer that supports albumin binding. Its published average molecular weight is ~4,113.6 Da. Semaglutide is a selective agonist at the GLP-1 receptor and is the active substance in the FDA-approved medicines Ozempic®, Wegovy®, and Rybelsus®. As a research peptide, it is used in preclinical incretin, glucose-regulation, and body-composition models.

What Is Tirzepatide?

Tirzepatide is a synthetic 39-residue peptide engineered from the glucose-dependent insulinotropic polypeptide (GIP) sequence, with modifications that give it activity at both the GIP receptor (GIP-R) and the GLP-1 receptor (GLP-1R). Published structural work describes 14 unique amino acids relative to native GIP, an Aib substitution at position 2 for DPP-4 resistance, and a C20 fatty diacid conjugated to lysine-20 through a γ-Glu/2xOEG linker that promotes albumin binding. Its average molecular weight is ~4,813.5 Da. Tirzepatide is the active substance in the FDA-approved medicines Mounjaro® and Zepbound®. As a research peptide, it is investigated in preclinical dual-incretin and metabolic models.

Semaglutide vs Tirzepatide: Side-by-Side

Attribute	Semaglutide	Tirzepatide
Peptide length	31 amino acids (GLP-1 positions 7–37)	39 amino acids
Backbone origin	GLP-1 analog	Engineered from GIP; 14 residues unique vs native GIP
Average molecular weight	~4,113.6 Da	~4,813.5 Da
Receptor pharmacology	Selective GLP-1R agonist	Dual GIP-R + GLP-1R agonist
Reported receptor balance	Selective for GLP-1R	Imbalanced: near-native potency at GIP-R, reduced potency at GLP-1R vs native GLP-1; biased toward cAMP over β-arrestin at GLP-1R
DPP-4 resistance	Aib at position 8	Aib at position 2
Fatty acid modification	C18 fatty diacid on Lys26 via γ-Glu / 2xOEG spacer	C20 fatty diacid on Lys20 via γ-Glu / 2xOEG linker
Reported plasma half-life	~165–168 h (once-weekly dosing supported in approved use)	~5 days (once-weekly dosing supported in approved use)
FDA-approved brands	Ozempic®, Wegovy®, Rybelsus®	Mounjaro®, Zepbound®
Research-supply form	Lyophilized powder in sealed vial (RUO)	Lyophilized powder in sealed vial (RUO)

Backbone Origin: GLP-1 vs GIP

Semaglutide and tirzepatide are often grouped together as “GLP-1 drugs,” but only semaglutide is a GLP-1 analog in the strict structural sense. Semaglutide’s peptide backbone is that of native human GLP-1(7–37) with three engineered changes. Tirzepatide’s backbone is engineered from GIP, with 14 residues that differ from native GIP and further modifications that let the same sequence engage the GLP-1 receptor as well. This distinction matters when reading pharmacology literature: findings framed against native GLP-1 do not automatically apply to tirzepatide, and vice versa.

Receptor Pharmacology: GLP-1 vs Dual GIP/GLP-1

Semaglutide acts as a selective agonist at the GLP-1 receptor and has no meaningful activity at the GIP receptor. Tirzepatide activates both receptors, but not in equal proportion. Published functional pharmacology describes tirzepatide as an imbalanced and biased dual agonist: it retains near-native potency at GIP-R, shows reduced potency at GLP-1R relative to native GLP-1, and at GLP-1R is biased in favour of cAMP signalling over β-arrestin recruitment. In practice this means that a study comparing the two peptides at “equimolar” doses is comparing two different receptor-engagement profiles, not two intensities of the same signal.

Molecular Modifications That Extend Half-Life

Both peptides carry engineered modifications that slow their clearance and support weekly dosing in their approved clinical formulations. Aib substitutions at DPP-4 cleavage-sensitive positions resist enzymatic degradation. A fatty diacid conjugated through a γ-Glu / 2xOEG spacer to a specific lysine promotes reversible binding to serum albumin, which shields the peptide from renal filtration and proteolysis and lengthens its plasma half-life. Semaglutide uses a C18 fatty diacid on Lys26; tirzepatide uses a longer C20 fatty diacid on Lys20. These modifications are the reason both molecules can be dosed weekly in their approved uses; they are also the reason a mass-spectrometry result will not match the mass of the unmodified GLP-1 or GIP sequence.

How Semaglutide and Tirzepatide Have Been Studied in Preclinical Research

Semaglutide has been characterized in in-vitro GLP-1 receptor binding and cAMP assays, in rodent glucose-tolerance and body-weight models, and in extensive registrational clinical trials underpinning its approved indications. Tirzepatide has been characterized in in-vitro dual-receptor binding, cAMP, and β-arrestin assays, in rodent and non-human primate metabolic models, and in the SURPASS and SURMOUNT clinical trial programmes. In research-peptide catalog use, both compounds are investigated in preclinical incretin receptor pharmacology, glucose-regulation, and body-composition endpoints. Findings from the clinical trials of the approved medicines describe the sterile, pharmaceutical-grade formulations of these compounds, not research-supply vials.

FDA-Approved Medicine vs Research Peptide

Both semaglutide and tirzepatide are the active substances in FDA-approved prescription medicines. A research-peptide vial sold under For Research Use Only labelling shares the sequence of the active substance but is not the same product as the approved drug: the approved medicine is manufactured under cGMP, is sterile-filled with defined excipients, carries FDA-approved prescribing information, and is supported by pharmacovigilance obligations. A research-supply vial is a laboratory chemical for in-vitro and preclinical work and does not carry any of those. Sequence identity does not transfer the safety, sterility, or approved-use status of the medicine to the research vial. See What Is a Research Peptide? for how RUO labelling and FDA approval relate to one another.

Handling and Verification — What the Two Peptides Share

Both peptides are supplied as lyophilized powder in sealed multi-use vials and are typically reconstituted in bacteriostatic water at research concentrations. Sealed lyophilized vials are generally stored at −20 °C or −80 °C; reconstituted vials are refrigerated for short-term use and aliquoted at −20 to −80 °C where the formulation allows. Actual usable life in solution depends on the peptide sequence, formulation, diluent, pH, and freeze–thaw handling. The batch Certificate of Analysis is the authoritative reference. Two verification checks apply before any experiment:

Read the batch Certificate of Analysis. Confirm HPLC purity, mass-spectrometric identity, appearance, counterion, water content, and (for cell-based work) endotoxin. See How to Read a Peptide Certificate of Analysis.
Match the reported mass to the expected mass for the exact chemical species named on the label. Semaglutide should be close to ~4,114 Da; tirzepatide should be close to ~4,814 Da. A deviation of hundreds of daltons indicates the wrong molecule, a missing modification, or a labelling problem.

Key Takeaways

Semaglutide is a selective GLP-1 receptor agonist; tirzepatide is a dual GIP + GLP-1 receptor agonist.
Semaglutide’s backbone is a GLP-1 analog; tirzepatide’s backbone is engineered from GIP.
Semaglutide is 31 amino acids (~4,114 Da); tirzepatide is 39 amino acids (~4,814 Da).
Tirzepatide is imbalanced and biased at its two receptors, with near-native potency at GIP-R and reduced potency at GLP-1R relative to native GLP-1.
Both peptides are FDA-approved medicines; a research-supply vial of either is a laboratory chemical, not the approved drug.

Frequently Asked Questions

Is tirzepatide the same as semaglutide?

No. They are different peptides. Semaglutide is a 31-amino-acid GLP-1 analog (~4,114 Da) that activates only the GLP-1 receptor. Tirzepatide is a 39-amino-acid peptide (~4,814 Da) engineered from the GIP sequence that activates both the GIP and GLP-1 receptors. They differ in length, sequence, molecular weight, backbone origin, and receptor pharmacology.

Is tirzepatide a GLP-1 analog?

Not in the strict structural sense. Tirzepatide’s backbone is engineered from GIP, not GLP-1, with modifications that let the peptide also engage the GLP-1 receptor. It is often grouped with GLP-1 agonists in general discussion, but structurally it is a dual GIP/GLP-1 agonist based on the GIP backbone.

Is semaglutide stronger than tirzepatide?

“Stronger” is not a well-defined comparison across two different receptor-engagement profiles. Semaglutide acts only at GLP-1R; tirzepatide activates GIP-R and GLP-1R in an imbalanced way and is biased at GLP-1R toward cAMP over β-arrestin. Reported potency and outcome differences depend on the assay, the model, and the endpoint measured.

What is the molecular weight of semaglutide and tirzepatide?

Semaglutide has an average molecular weight of approximately 4,113.6 Da. Tirzepatide has an average molecular weight of approximately 4,813.5 Da. The difference reflects the additional amino acids in tirzepatide plus its longer C20 fatty-diacid modification.

Do semaglutide and tirzepatide have the same half-life?

Both are engineered for long plasma persistence to support once-weekly dosing in their approved medical uses. Published values are approximately 165–168 hours for semaglutide and approximately 5 days for tirzepatide. Both figures describe the sterile pharmaceutical formulation of each compound in clinical use, not a research-supply vial.

Are research-peptide semaglutide and tirzepatide the same as Ozempic®, Wegovy®, Mounjaro®, or Zepbound®?

No. The approved medicines are FDA-regulated drugs manufactured under cGMP with sterile fill, defined excipients, and approved prescribing information. A research-peptide vial shares the peptide sequence but is a laboratory chemical sold under For Research Use Only labelling and does not carry those pharmaceutical-grade attributes. Sequence identity does not equal product identity.

How are semaglutide and tirzepatide verified in a research-supply vial?

By reading the batch Certificate of Analysis. Confirm HPLC purity, mass-spectrometric identity against the expected average mass (~4,114 Da for semaglutide; ~4,814 Da for tirzepatide), counterion, and endotoxin data where the downstream assay requires it. A significant deviation from the expected mass indicates the wrong molecule or a labelling problem.

Are semaglutide and tirzepatide FDA-approved?

Yes, as pharmaceutical medicines. Semaglutide is the active substance in Ozempic®, Wegovy®, and Rybelsus®. Tirzepatide is the active substance in Mounjaro® and Zepbound®. Research-supply vials of either peptide are not FDA-approved products; they are RUO laboratory chemicals for in-vitro and preclinical work only.

References

Lau J, Bloch P, Schäffer L, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem 2015;58(18):7370–80. Structural rationale for the Aib8, Arg34, and C18 fatty-diacid modifications and albumin-binding half-life extension. Indexed at PubMed.
Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab 2018;18:3–14. First-in-class characterization of tirzepatide as a dual GIP/GLP-1 agonist. Indexed at PubMed.
Willard FS, Douros JD, Gabe MBN, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight 2020;5(17):e140532. Functional pharmacology showing near-native GIP-R potency, reduced GLP-1R potency, and cAMP-biased GLP-1R signalling. PMID 32730231.
Sun B, Willard FS, Feng D, et al. Structural determinants of dual incretin receptor agonism by tirzepatide. Proc Natl Acad Sci USA 2022;119(13):e2116506119. Cryo-EM structures of tirzepatide at the GIP-R and GLP-1R. DOI: 10.1073/pnas.2116506119.
Zhao F, Zhou Q, Cong Z, et al. Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors. Nat Commun 2022;13:1057. DOI: 10.1038/s41467-022-28683-0.
Chemical Entities of Biological Interest (ChEBI). Tirzepatide (CHEBI:194186). Molecular formula, average and monoisotopic masses.
U.S. Food & Drug Administration. Ozempic®, Wegovy®, Rybelsus®, Mounjaro®, and Zepbound® prescribing information. Approved-drug labelling for semaglutide and tirzepatide.

Research use disclaimer. All peptides sold by AppealLabs are labelled FOR RESEARCH USE ONLY · NOT FOR HUMAN CONSUMPTION. Content on this page describes preclinical scientific literature, structural chemistry, and regulatory context only, and is not medical advice. Nothing here should be interpreted as diagnosing, treating, curing, or preventing any disease, or as guidance for human use of any peptide, including semaglutide, tirzepatide, or their FDA-approved medicines.